Monoclonal Antibody Provides Itch Relief for Prurigo Nodularis Monoclonal Antibody Provides Itch Relief for Prurigo Nodularis

An experimental treatment for prurigo nodularis (PN) can reduce itching by 53% over four weeks, according to a phase-2 test of subcutaneous nemolizumab. The reduction was only 20% with placebo therapy.Reuters Health Information
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Dermatology News Source Type: news